By Paul Arnold and Maggie Fick ZURICH (Reuters) -Swiss drugmaker Novartis is ending its use of diverse panels for all of its ...

By Paul Arnold, Maggie Fick ZURICH (Reuters) -Swiss drugmaker Roche has abandoned global diverse workforce targets and ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Novartis’s (NVS) parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites was granted FDA orphan ...

Novartis (NVS) announced that oral Fabhalta, iptacopan, has received U.S. Food and Drug Administration approval for the ...

The notice comes three months after the pharmaceutical giant said it would eliminate 139 jobs at the location between February and August.

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...

Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by the United ...

The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...